Literature DB >> 24100919

Association of systemic and intra-articular osteoclastogenic potential, pro-inflammatory mediators and disease activity with the form of inflammatory arthritis.

Marina Ikić1, Zrinka Jajić, Elvira Lazić, Sanja Ivčević, Frane Grubišić, Ana Marušić, Nataša Kovačić, Danka Grčević.   

Abstract

PURPOSE: We aimed to assess osteoclastogenic potential of peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) in different forms of arthritis and to correlate it with inflammatory mediators within intra-articular and circulatory compartments.
METHODS: Paired PBMC and SFMC samples of patients with rheumatoid arthritis (RA; n = 10) and psoriatic arthritis (PsA; n = 10), and PBMC of healthy controls were cultured to assess osteoclastogenic potential by the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts (OCs) and expression of OC-related genes (receptor activator of nuclear factor-κΒ (RANK), cFMS, and TRAP). Osteoclastogenesis was correlated with the arthritis-related inflammatory indicators in serum and synovial fluid (SF).
RESULTS: Number of OCs differentiated from PBMC was significantly higher in RA and PsA compared with control, with RA having more OCs compared with PsA. There was no difference in SFMC OC number between arthritic patients, but RANK expression in OCs differentiated from SFMC was higher in PsA compared with RA. SF of PsA patients more potently induced OC differentiation from control CD3(-)CD19(-)CD56(-)CD11b(+)CD115(+) PBMC compared with RA, paralleled with higher RANK-ligand expression in PsA SFMC. Positive correlations of OC number with erythrocyte sedimentation rate, serum level of CCL2, and PBMC gene expression of interleukin-18 and Fas-ligand were observed.
CONCLUSION: Osteoclastogenic potential is systemically enhanced in patients with RA, paralleled by disordered systemic and local expression of proinflammatory mediators, whereas PsA involves specific deregulation in RANKL/RANK axis. Our study reveals arthritis-specific mediators associated with the form of arthritis, indicating clinical relevance for diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100919      PMCID: PMC3890142          DOI: 10.1007/s00264-013-2121-0

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  25 in total

Review 1.  Fas (CD95)-related apoptosis and rheumatoid arthritis.

Authors:  S L Peng
Journal:  Rheumatology (Oxford)       Date:  2005-09-13       Impact factor: 7.580

2.  Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES.

Authors:  Michael S Kim; Carly L Magno; Christopher J Day; Nigel A Morrison
Journal:  J Cell Biochem       Date:  2006-02-15       Impact factor: 4.429

3.  Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis.

Authors:  Hyewon Park; Youn-Kwan Jung; Ok-Jin Park; Yeon Ju Lee; Je-Yong Choi; Youngnim Choi
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation.

Authors:  Michael S Kim; Christopher J Day; Nigel A Morrison
Journal:  J Biol Chem       Date:  2005-02-17       Impact factor: 5.157

5.  Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.

Authors:  D Grcević; I K Lukić; N Kovacić; S Ivcević; V Katavić; A Marusić
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

6.  Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.

Authors:  Y H Zhang; A Heulsmann; M M Tondravi; A Mukherjee; Y Abu-Amer
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

7.  Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.

Authors:  S-M Dai; K Nishioka; K Yudoh
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

8.  IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  Wei Zhang; Xiao-Liang Cong; Yang-Hua Qin; Zheng-Wen He; Dong-Yi He; Sheng-Ming Dai
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

9.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.

Authors:  Yukiko Komano; Toshihiro Nanki; Kenji Hayashida; Ken Taniguchi; Nobuyuki Miyasaka
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  11 in total

1.  Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.

Authors:  Weiqiang Chen; Suan-Sin Foo; Adam Taylor; Aleksei Lulla; Andres Merits; Linda Hueston; Mark R Forwood; Nicole C Walsh; Natalie A Sims; Lara J Herrero; Suresh Mahalingam
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

2.  Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.

Authors:  M Ikić Matijašević; D Flegar; N Kovačić; V Katavić; T Kelava; A Šućur; S Ivčević; H Cvija; E Lazić Mosler; I Kalajzić; A Marušić; D Grčević
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

Review 3.  Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.

Authors:  Alan Sućur; Vedran Katavić; Tomislav Kelava; Zrinka Jajić; Natasa Kovačić; Danka Grčević
Journal:  Int Orthop       Date:  2014-06-10       Impact factor: 3.075

4.  Sympathetic Neurotransmitters Modulate Osteoclastogenesis and Osteoclast Activity in the Context of Collagen-Induced Arthritis.

Authors:  Dominique Muschter; Nicole Schäfer; Hubert Stangl; Rainer H Straub; Susanne Grässel
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  Effect of Vitamin D on Peripheral Blood Mononuclear Cells from Patients with Psoriasis Vulgaris and Psoriatic Arthritis.

Authors:  Susana Cubillos; Nadine Krieg; Johannes Norgauer
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

6.  Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.

Authors:  Alan Sucur; Zrinka Jajic; Marinko Artukovic; Marina Ikic Matijasevic; Branimir Anic; Darja Flegar; Antonio Markotic; Tomislav Kelava; Sanja Ivcevic; Natasa Kovacic; Vedran Katavic; Danka Grcevic
Journal:  Arthritis Res Ther       Date:  2017-06-15       Impact factor: 5.156

Review 7.  What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?

Authors:  Teun J de Vries; Ismail El Bakkali; Thomas Kamradt; Georg Schett; Ineke D C Jansen; Patrizia D'Amelio
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

8.  Intermediate monocytes correlate with CXCR3+ Th17 cells but not with bone characteristics in untreated early rheumatoid arthritis.

Authors:  Christina Drevinge; Julia M Scheffler; Catalin Koro-Arvidsson; Daniel Sundh; Hans Carlsten; Inger Gjertsson; Catharina Lindholm; Mattias Lorentzon; Anna Rudin; Anna-Karin Hultgård Ekwall; Ulrika Islander
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

9.  Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways.

Authors:  Wei Shang; Ling-Jie Zhao; Xiao-Lei Dong; Zhi-Ming Zhao; Jing Li; Bei-Bei Zhang; Hui Cai
Journal:  Mol Med Rep       Date:  2016-08-25       Impact factor: 2.952

Review 10.  Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis.

Authors:  Bridie S Mulholland; Mark R Forwood; Nigel A Morrison
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.